bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
=== Alternative remedies === Examples include: Ackee fruit, Bajiaolian, Camphor, Copaltra, Cycasin, Garcinia, Kava leaves, pyrrolizidine alkaloids, Horse chestnut leaves, Valerian, Comfrey. Chinese herbal remedies: Jin Bu Huan, Ephedra, Shou Wu Pian, Bai Xian Pi.
When those prices are adjusted for inflation, however, then Gone with the Wind—which was the highest-grossing film outright for twenty-five years—is still the highest-grossing film of all time. All grosses on the list are expressed in U.S. dollars at their nominal value, except where stated otherwise.
== P == P42 MAP kinase -p53 - pancreatic polypeptide - parathyroid hormone receptor - partial pressure - passive transport - Pauling scale - PCR - peptide - peptide bond - peptide elongation factor - peptide elongation factor tu - peptide fragment - peptide initiation factor - peptide receptor - peptide termination factor - peripheral membrane protein - pesticide - pH - phage display - pharmaceutical - pharmacist - pharmacology - phenol - phenotype - phenyl group - phenylalanine - Philadelphia chromosome - phospholipid - phospholipid bilayer - phosphopeptide - phosphoprotein - phosphorus - phosphorylation - phosphoserine - phosphothreonine - phosphotyrosine - photobiology - photolysis - photophosphorylation - photoreceptor - photorespiration - photosynthesis - photosystem I - photosystem II - phototransduction - phylogenetics - phylogeny - physical chemistry - physiology - phytohaemagglutinin - pituitary hormone receptor - pituitary hormone-regulating hormone receptor - plant protein - plasma membrane - plasmid - plasmin - plasminogen - platelet glycoprotein GPIb-IX complex - platelet membrane glycoprotein - platelet-derived growth factor - platelet-derived growth factor receptor - polymer - polymerase chain reaction - polymerization - polymyxin - polymyxin B - polyomavirus transforming antigen - polypeptide - polysaccharide - porphyrin - Posttranslational modification - potassium - potassium channel - potential energy - pregnancy proteins - primary nutritional groups - primary structure - primer - prion - progesterone receptor - prokaryote - prolactin - prolactin receptor - proline - promoter - prostaglandin e receptor - prostaglandin receptor - protein - protein biosynthesis - Protein Data Bank - protein design - protein expression - protein folding - protein isoform - protein nuclear magnetic resonance spectroscopy - protein P16 - protein P34cdc2 - protein precursor - protein structure prediction - protein subunit - protein synthesis - protein targeting - protein translocation - protein-tyrosine kinase - protein-tyrosine-phosphatase - proteinoid - proteomics - protirelin - proto-oncogene - proto-oncogene proteins - proto-oncogene protein C-kit - proto-oncogene proteins c-abl - proto-oncogene proteins c-bcl-2 - Proto-oncogene proteins c-fos - proto-oncogene proteins c-jun - proto-oncogene proteins c-mo - proto-oncogene proteins c-myc - proto-oncogene proteins c-raf - proton - proton pump - protozoan proteins - purine - purinergic P1 receptor - purinergic P2 receptor - purinergic receptor - pyridine - pyrimidine - pyruvate - pyruvate oxidation
== Use and effects == Salvinorin A is active at doses as low as 200 μg. It has only been administered to humans in a few studies, one showing that its effects peaked at about 2 minutes, that its subjective effects may overlap with those of serotonergic psychedelics, and that it temporarily impairs recall and recognition memory. Like most other agonists of KOR, salvinorin A produces sedation, psychotomimesis, dysphoria, anhedonia, and depression.
Sources: en.wikipedia.org
=== Hormonal evaluation === Similar to humans, a diagnosis of hypersomatotropism in cats and dogs requires demonstration of growth hormone excess or heightened IGF-1 concentrations. Growth hormone levels can be measured with a radioimmunoassay. However the cost may impact availability of this. All cats with hypersomatotropism that have been tested in studies displayed increased growth hormone levels. Some cats had significantly increased levels; in other cats, the increase was only slightly above normal levels. Cats in those studies were likely in the later stages of the disease. A single instance of elevated growth hormone levels is not indicative of hypersomatotropism, it can be the result of a secretory pulse and mildly increased growth hormone levels have been observed in diabetic cats without hypersomatotropism. The recommended practice is for several tests with 10 minute intervals. IGF-1 levels can be detected with a blood test. The vast majority of cats with hypersomatotropism have increased IGF-1 levels, most dogs with hypersomatotropism have increased IGF-1 levels. Normal levels of IGF-1 have been seen in a few cats, potentially due to these cats being at the early stages of the disease. Other causes need to be investigated in cats with normal IGF-1 levels and suspected hypersomatotropism. IGF-1 levels may be lower due to lymphoma or other diseases. IGF-1 levels can be normal in cats with hypersomatotropism when the measurement is taken prior to insulin therapy.
Myomeres are overlapping "cones" of muscle fibers bound by connective tissue. The shape of myomeres varies by species. Myomeres are commonly zig-zaged, being stacks or lines of muscle fibers shaped like "V" (lancelets), "W" (fishes), or straight (tetrapods). Generally, cyclostome myomeres are arranged in vertical strips while those of jawed fishes are folded in a complex manner due to their derived nature and evolution of advanced swimming capability. Specifically, myomeres of elasmobranchs and eels are W-shaped, while the myomeres of tetrapods, such as mudpuppies, run vertically and do not display complex folding. Myomeres overlap each other in succession, meaning myomere activation also allows neighboring myomeres to activate. They are innervated by spinal nerves, which pass into each myomere. Myomeres are made up of myoglobin-rich dark muscle as well as white muscle. Dark muscles generally function as slow-twitch muscle fibers while white muscle is composed of fast-twitch fibers. In gnathostomes, the myomeres are separated by myoseptal tendons. Specifically, these are the myorhabdoid tendons, the lateral tendons, the epineural tendon, and the epipleural tendon.
Like dry ice, the main use of liquid nitrogen is for cooling to low temperatures. It is used in the cryopreservation of biological materials such as blood and reproductive cells (sperm and eggs). It is used in cryotherapy to remove cysts and warts on the skin by freezing them. It is used in laboratory cold traps, and in cryopumps to obtain lower pressures in vacuum pumped systems. It is used to cool heat-sensitive electronics such as infrared detectors and X-ray detectors. Other uses include freeze-grinding and machining materials that are soft or rubbery at room temperature, shrink-fitting and assembling engineering components, and more generally to attain very low temperatures where necessary. Because of its low cost, liquid nitrogen is often used for cooling even when such low temperatures are not strictly necessary, such as refrigeration of food, freeze-branding livestock, freezing pipes to halt flow when valves are not present, and consolidating unstable soil by freezing whenever excavation is going on underneath.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.